James A. Feldman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James A. Feldman has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Susan S. Fish
Boston University Chobanian & Avedisian School of Medicine
10 shared publications Patricia M. Mitchell
Boston Medical Center, MA, USA
9 shared publicationsJohn L. Griffith
Divisions of Clinical Care Research and Cardiology
5 shared publicationsJoni R. Beshansky
Divisions of Clinical Care Research and Cardiology
5 shared publicationsCasey M. Rebholz
Tulane University School of Medicine, New Orleans, LA 70112-2699, USA
4 shared publicationsHarry P. Selker
Divisions of Clinical Care Research and Cardiology
4 shared publications
Latest Publications
- Open Access
- 1 September 2022
- Published by Wiley in Ethics & Human Research
- Vol. 44 (5) , 42-48
Informed Consent for Placebo‐Controlled Trials: Do Ethics and Science Conflict?
The use of a placebo has been considered the best method for controlling bias in a prospective randomized clinical trial and provides the most rigorous test of treatment efficacy for evaluating a medical therapy. Placebos commonly produce clinically important effects particularly in studies where the primary outcomes are subjective. Yet the potential beneficial or harmful effects of placebos are often not addressed in designing a clinical trial, calculating the sample size, seeking consent, or interpreting clinical trial results. In this manuscript, we use an actual study to indicate three approaches that might be considered in seeking informed consent for placebo-controlled trials, and we explore the fundamental ethical and scientific complexities involved with each.
- 1 September 2022
- Published by Wiley in Ethics & Human Research
- Vol. 44 (5) , 42-48
Open AccessInformed Consent for Placebo‐Controlled Trials: Do Ethics and Science Conflict?
The use of a placebo has been considered the best method for controlling bias in a prospective randomized clinical trial and provides the most rigorous test of treatment efficacy for evaluating a medical therapy. Placebos commonly produce clinically important effects particularly in studies where the primary outcomes are subjective. Yet the potential beneficial or harmful effects of placebos are often not addressed in designing a clinical trial, calculating the sample size, seeking consent, or interpreting clinical trial results. In this manuscript, we use an actual study to indicate three approaches that might be considered in seeking informed consent for placebo-controlled trials, and we explore the fundamental ethical and scientific complexities involved with each.
- Open Access
- 1 May 2021
- Published by Elsevier in JACEP Open
- Vol. 2 (3) , e12427
False negative point‐of‐care urine pregnancy tests in an urban academic emergency department: a retrospective cohort study
- 1 May 2021
- Published by Elsevier in JACEP Open
- Vol. 2 (3) , e12427
Open AccessFalse negative point‐of‐care urine pregnancy tests in an urban academic emergency department: a retrospective cohort study
- 14 November 2019
- Published by Wiley in Academic Emergency Medicine
- Vol. 27 (3) , 256-258
When the Aberrant Becomes the Accepted: The Rise of Hallway Care in Emergency Medicine
- 14 November 2019
- Published by Wiley in Academic Emergency Medicine
- Vol. 27 (3) , 256-258
When the Aberrant Becomes the Accepted: The Rise of Hallway Care in Emergency Medicine
- 13 March 2019
- Published by SAGE Publications in Journal of Empirical Research on Human Research Ethics
- Vol. 14 (2) , 117-125
Variability in Institutional Board Review for a Multisite Assessment of Resident Professionalism
Residents serve as both trainees and employees and can be considered potentially vulnerable research participants. This can lead to variation in the institutional review board (IRB) review. We studied sites participating in the Assessment of Professional Behaviors Study sponsored by the National Board of Medical Examiners (2009-2011). Of the 19 sites, all but one were university affiliated. IRB review varied; 2/19 did not submit to a local IRB, 4/17 (23%) were exempt, 11/17 (65%) were expedited, and 2/17 (12%) required full Board review; 12/17 (71%) required written informed consent. The interval from submission to approval was 1 to 2 months (8/17); the range was 1 to 7 months. Although most stated there were no major barriers to approval, the most common concern was resident coercion and loss of confidentiality. Local IRB review of this educational research study varied.
- 13 March 2019
- Published by SAGE Publications in Journal of Empirical Research on Human Research Ethics
- Vol. 14 (2) , 117-125
Variability in Institutional Board Review for a Multisite Assessment of Resident Professionalism
Residents serve as both trainees and employees and can be considered potentially vulnerable research participants. This can lead to variation in the institutional review board (IRB) review. We studied sites participating in the Assessment of Professional Behaviors Study sponsored by the National Board of Medical Examiners (2009-2011). Of the 19 sites, all but one were university affiliated. IRB review varied; 2/19 did not submit to a local IRB, 4/17 (23%) were exempt, 11/17 (65%) were expedited, and 2/17 (12%) required full Board review; 12/17 (71%) required written informed consent. The interval from submission to approval was 1 to 2 months (8/17); the range was 1 to 7 months. Although most stated there were no major barriers to approval, the most common concern was resident coercion and loss of confidentiality. Local IRB review of this educational research study varied.
- Open Access
- 22 August 2016
- Published by SAGE Publications in Public Health Reports®
- Vol. 131 (5) , 671-675
Identifying Patients for Overdose Prevention With ICD-9 Classification in the Emergency Department, Massachusetts, 2013-2014
The national rise in opioid overdose deaths signifies a need to integrate overdose prevention within healthcare delivery settings. The emergency department (ED) is an opportune location for such interventions. To effectively integrate prevention services, the target population must be clearly defined. We used ICD-9 discharge codes to establish and apply overdose risk categories to ED patients seen from January 1, 2013 to December 31, 2014 at an urban safety-net hospital in Massachusetts with the goal of informing ED-based naloxone rescue kit distribution programs. Of 96,419 patients, 4,468 (4.6%) were at increased risk of opioid overdose, defined by prior opioid overdose, misuse, or polysubstance misuse. A small proportion of those at risk were prescribed opioids on a separate occasion. Use of risk categories defined by ICD-9 codes identified a notable proportion of ED patients at risk for overdose, and provides a systematic means to prioritize and direct clinical overdose prevention efforts.
- 22 August 2016
- Published by SAGE Publications in Public Health Reports®
- Vol. 131 (5) , 671-675
Open AccessIdentifying Patients for Overdose Prevention With ICD-9 Classification in the Emergency Department, Massachusetts, 2013-2014
The national rise in opioid overdose deaths signifies a need to integrate overdose prevention within healthcare delivery settings. The emergency department (ED) is an opportune location for such interventions. To effectively integrate prevention services, the target population must be clearly defined. We used ICD-9 discharge codes to establish and apply overdose risk categories to ED patients seen from January 1, 2013 to December 31, 2014 at an urban safety-net hospital in Massachusetts with the goal of informing ED-based naloxone rescue kit distribution programs. Of 96,419 patients, 4,468 (4.6%) were at increased risk of opioid overdose, defined by prior opioid overdose, misuse, or polysubstance misuse. A small proportion of those at risk were prescribed opioids on a separate occasion. Use of risk categories defined by ICD-9 codes identified a notable proportion of ED patients at risk for overdose, and provides a systematic means to prioritize and direct clinical overdose prevention efforts.
- 1 September 2015
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 33 (9) , 1197-1200
Incentives to participate in clinical trials: practical and ethical considerations
- 1 September 2015
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 33 (9) , 1197-1200
Incentives to participate in clinical trials: practical and ethical considerations
- 1 April 2015
- Published by Elsevier in The Journal of Emergency Medicine
- Vol. 48 (4) , 424-431.e1
Characteristics of Emergency Department “Doctor Shoppers”
- 1 April 2015
- Published by Elsevier in The Journal of Emergency Medicine
- Vol. 48 (4) , 424-431.e1
Characteristics of Emergency Department “Doctor Shoppers”
- 1 September 2014
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 64 (3) , 229-30
It takes a system to treat a pneumothorax.
- 1 September 2014
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 64 (3) , 229-30
It takes a system to treat a pneumothorax.
- 1 May 2014
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 63 (5) , 589-597.e7
“No Diversion”: A Qualitative Study of Emergency Medicine Leaders in Boston, MA, and the Effects of a Statewide Diversion Ban Policy
- 1 May 2014
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 63 (5) , 589-597.e7
“No Diversion”: A Qualitative Study of Emergency Medicine Leaders in Boston, MA, and the Effects of a Statewide Diversion Ban Policy
- 1 May 2012
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 19 (3) , 180-184
Are Patients Aware of Angiotensin-Converting Enzyme Inhibitor–Associated Adverse Effects?
It is important for patients to understand the potential adverse effects (AEs) of their daily medications. Because associated adverse effects (ACEIs) may result in life-threatening angioedema, we sought to assess patients' level of awareness of ACEI AEs, determine if patients have an appropriate action plan in the event of an ACEI AE, determine if a brief educational intervention in the emergency department (ED) could improve knowledge about ACEI AEs. This was a prospective in-person survey conducted between August and December 2008 in a large urban academic ED. The survey instrument was used to collect data on demographics, recognition of ACEI AEs, and action plans. A follow-up survey to assess recall of AEs was done 7 days after ED discharge. Of 208 eligible patients, 113 enrolled: sixty-five (58%) were females, median age was 55 years [interquartile range (IQR) 47–64]. The majority of participants (69%) had a high-school diploma or less. On a 5-point Likert scale (5 = “very important”), the median reported level of overall concern for ACEI AEs was 5 (IQR 4–5). Twenty-seven (25%) of the participants reported being told that ACEIs have potential AEs at the time of the initial prescription. Correct identification of potential ACEI-associated AEs in the ED was variable with a median of 8 of 16 correctly answered questions (IQR 6–10). At follow-up, the median score was 9 (IQR 6–10). There was no association between educational level and number of correct AE responses (P = 0.10). Despite a high level of expressed concern regarding ACEI AEs, patients' knowledge of AEs was poor, and recall was minimally improved at follow-up. Most patients have a plan in the event of an AE.
- 1 May 2012
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 19 (3) , 180-184
Are Patients Aware of Angiotensin-Converting Enzyme Inhibitor–Associated Adverse Effects?
It is important for patients to understand the potential adverse effects (AEs) of their daily medications. Because associated adverse effects (ACEIs) may result in life-threatening angioedema, we sought to assess patients' level of awareness of ACEI AEs, determine if patients have an appropriate action plan in the event of an ACEI AE, determine if a brief educational intervention in the emergency department (ED) could improve knowledge about ACEI AEs. This was a prospective in-person survey conducted between August and December 2008 in a large urban academic ED. The survey instrument was used to collect data on demographics, recognition of ACEI AEs, and action plans. A follow-up survey to assess recall of AEs was done 7 days after ED discharge. Of 208 eligible patients, 113 enrolled: sixty-five (58%) were females, median age was 55 years [interquartile range (IQR) 47–64]. The majority of participants (69%) had a high-school diploma or less. On a 5-point Likert scale (5 = “very important”), the median reported level of overall concern for ACEI AEs was 5 (IQR 4–5). Twenty-seven (25%) of the participants reported being told that ACEIs have potential AEs at the time of the initial prescription. Correct identification of potential ACEI-associated AEs in the ED was variable with a median of 8 of 16 correctly answered questions (IQR 6–10). At follow-up, the median score was 9 (IQR 6–10). There was no association between educational level and number of correct AE responses (P = 0.10). Despite a high level of expressed concern regarding ACEI AEs, patients' knowledge of AEs was poor, and recall was minimally improved at follow-up. Most patients have a plan in the event of an AE.